Clinical trial NCT01275144: A Study of the Effect of LY2216684 on Lorazepam
Official title: Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Lorazepam in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Major Depressive Disorder
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2011-01-12
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684. Information about any side effects that may occur will also be collected.


Eligibility criteria: Inclusion Criteria:

* Are overtly healthy, as determined by medical history and physical examination.
* Male participants - Agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug.
* Female participants - Are women of child-bearing potential who test negative for pregnancy at the time of enrollment, have used a reliable method of birth control for 6 weeks prior to administration of study drug, and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; or Women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause (at least 1 year without menses or 6 months without menses and a follicle stimulating hormone \[FSH\] \>40 milli-international Units per milliliter \[mIU/mL\]).
* Have a body weight \>50 kilogram (kg).
* Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator (potassium, magnesium, and calcium values must be within the normal range).
* Have venous access sufficient to allow blood sampling as per the protocol.
* Have normal blood pressure and pulse rate (sitting position) as determined by the investigator.
* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
* Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site.

Exclusion Criteria:

* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device other than the study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
* Have known allergies to LY2216684, lorazepam, benzodiazepines, or related compounds.
* Are persons who have previously completed or withdrawn from this study or any other study investigating LY2216684 within 6 months prior to screening.
* Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.
* Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
* Have a history or show evidence of significant active neuropsychiatric disease or have a history of suicide attempt or ideation.
* Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
* Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.
* Show evidence of hepatitis C and/or positive hepatitis C antibody.
* Show evidence of hepatitis B and/or positive hepatitis B surface antigen.
* Are women with a positive pregnancy test or women who are lactating.
* Intend to use over-the-counter or prescription medication (including hormonal contraceptives) within 14 days prior to dosing unless deemed acceptable by the investigator and Sponsor's medical monitor, except for influenza vaccinations.
* Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of Uridine 5'-diphospho -glucuronosyltransferase (UGT) within 30 days prior to dosing.
* Have donated blood of more than 500 mL within the last month.
* Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling to stop alcohol consumption 48 hours prior to each study period and while resident at the clinical research unit (CRU) (1 unit = 12 ounces (oz) or 360 millimeters (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
* Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any participants unwilling to adhere to study caffeine restrictions.
* Have used any tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to enrollment.
* Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment and during the study.
* Have a documented or suspected history of acute narrow angle glaucoma.
* Have Gilbert's Syndrome
* Participants determined to be unsuitable by the investigator for any reason.

Primary outcomes:
measure: Pharmacokinetics of Lorazepam, Maximum Plasma Concentration (Cmax)
timeFrame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose
measure: Pharmacokinetics of Lorazepam, Time to Maximum Plasma Concentration (Tmax)
timeFrame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose
measure: Pharmacokinetics of Lorazepam, Area Under the Plasma Concentration Curve (AUC) From Time 0 to Infinity (∞)
timeFrame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose
Secondary outcomes:
measure: Change From Baseline in Cognitive Function-Simple Reaction Time
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Digit Vigilance Speed
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Digit False Alarms
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Choice Reaction Time
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI)
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Numeric Working Memory Speed
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Immediate Word Recall Errors
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Delayed Word Recall Errors
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI)
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Word Recognition Speed
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI)
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Picture Recognition Speed
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Tracking Average Distance From Target
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Postural Stability
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Self-rated Alertness
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Self-rated Contentment
timeFrame: Baseline, 2, 4, 8 hours on Day 3
measure: Change From Baseline in Cognitive Function-Self-rated Calmness
timeFrame: Baseline, 2, 4, 8 hours on Day 3
Other outcomes:
Locations:
city: Leeds
country: United Kingdom
facility: For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References: